ArticleFrontiers in microbiology2025
Genomic and phenotypic characterization of two novel human-derived
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genomic sequencing of vineyard-isolatedFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: We isolated and genomically sequenced two novel Results: Comparative genomic analysis revealed distinct genetic architectures between LLR2 and LLR3, reflecting divergent evolutionary trajectories. Functionally, pronounced strain-specific differences were observed: LLR3 produced the antimicrobial compound reuterin, while LLR2 did not. In co-culture with LS174T cells, both strains decrease the production of Mucin-2, a key component of the gut barrier, with LLR2 showing significantly greater efficacy. Conversely, in the hCMEC/D3 inflammation model, LLR3 demonstrated a significantly stronger anti-inflammatory effect, suppressing the LPS-induced expression of IL-6 and TNF- Conclusion: This study expands the genomic repository of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.